A Case of Cicatricial Alopecia Associated with Erlotinib
Annals of Dermatology
;
: S350-S353, 2011.
Artículo
en Inglés
| WPRIM
| ID: wpr-165612
ABSTRACT
Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its role in tumor cells, EGFR is also an important regulator of growth and differentiation in the skin and hair. Therefore, EGFR-TKIs have been associated with a number of cutaneous side effects including follicular acneiform eruptions, cutaneous xerosis, chronic paronychia, desquamation, seborrheic dermatitis, and hair texture changes. Herein, we report a rare case of a 61-year-old woman who was treated with erlotinib and experienced cicatricial alopecia.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Paroniquia
/
Quinazolinas
/
Piel
/
Proteínas Tirosina Quinasas
/
Erupciones Acneiformes
/
Dermatitis Seborreica
/
Carcinoma de Pulmón de Células no Pequeñas
/
Alopecia
/
Receptores ErbB
/
Clorhidrato de Erlotinib
Límite:
Femenino
/
Humanos
Idioma:
Inglés
Revista:
Annals of Dermatology
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS